Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
What are your thoughts on the applicability and utility of the PREVENT equation and how it compares to the PCE for ASCVD risk assessment?
Related Questions
What are some general thoughts you have on the clinical utility and value of high sensitivity troponin in patients when there is little clinical evidence for acute MI or acute decompensated heart failure, and lack of evidence to support non-ischemic myocardial injury?
How do you counsel patients on wearable heart monitor devices when they ask about specific products and diagnostic accuracy of these devices available on the market?
When would you consider ordering additional testing such as hs-CRP, lipoprotein A levels, or CAC scoring to further risk stratify otherwise healthy pre-menopausal women with a prior history of pregnancy-related hypertension, diabetes, or premature births?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
For isolated and very high lipoprotein (a) levels (LDL of > 140, has an Lp(a) > 100) in a patient with no cardiac symptoms or risk factors, would you start lipid lowering treatment, such as with a PCSK9i if they develop statin intolerance?
Is bupropion, for tobacco cessation, safe in patients with a history of childhood seizures (either isolated or childhood epilepsy)?
What other considerations for hyperlipidemia management would you have for a patient with multiple prior PCIs whose LDL remains above goal on high intensity statin, ezetimibe, and evolocumab (assuming compliant with medications)?
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
How do you approach the management of aortic stenosis in an elderly, frail patient with multiple comorbidities who is symptomatic but considered high risk for surgical aortic valve replacement?
